Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review

被引:44
作者
Arroll, Megan Anne [1 ]
Wilder, Lorraine [2 ]
Neil, James [2 ]
机构
[1] Food Brain, London SW15 6DT, England
[2] Ctr Nutr Educ & Lifestyle Management, Wokingham RG40 1DH, Berks, England
关键词
Schizophrenia; Mental health; Nutrition; Personalised medicine; Adjunct treatment; POLYUNSATURATED FATTY-ACIDS; PLASMA MELATONIN LEVELS; ONE-CARBON METABOLISM; VITAMIN-D DEFICIENCY; N-ACETYL-CYSTEINE; ALPHA-LIPOIC ACID; DOUBLE-BLIND; OXIDATIVE STRESS; METHYLENETETRAHYDROFOLATE REDUCTASE; RELAPSED SCHIZOPHRENICS;
D O I
10.1186/1475-2891-13-91
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Schizophrenia is a chronic condition that impacts significantly not only on the individual and family, but the disorder also has wider consequences for society in terms of significant costs to the economy. This highly prevalent condition affects approximately 1% of the worldwide population, yet there are few therapeutic options. The predominant treatment strategy for schizophrenia is anti-psychotic medication (with or without additional talking therapy) even though this approach lacks efficacy in managing the negative symptoms of the condition, is not effective in one-third of the patient group and the side effects of the medication can be severe and debilitating. In recent years, a number of pathophysiological processes have been identified in groups of people with schizophrenia including oxidative stress, one-carbon metabolism and immune-mediated responses. A number of studies have shown that these altered physiological mechanisms can be ameliorated by nutritional interventions in some individuals with schizophrenia. This review briefly describes the aforementioned processes and outlines research that has investigated the utility of nutritional approaches as an adjunct to anti-psychotic medication including antioxidant and vitamin B supplementation, neuroprotective and anti-inflammatory nutrients and exclusion diets. Whilst none of these interventions provides a 'one-size-fits-all' therapeutic solution, we suggest that a personalised approach warrants research attention as there is growing agreement that schizophrenia is a spectrum disorder that develops from the interplay between environmental and genetic factors.
引用
收藏
页数:9
相关论文
共 112 条
  • [1] ADLER LA, 1993, AM J PSYCHIAT, V150, P1405
  • [2] A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia
    Akter, K.
    Gallo, D. A.
    Martin, S. A.
    Myronyuk, N.
    Roberts, R. T.
    Stercula, K.
    Raffa, R. B.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (02) : 132 - 139
  • [3] Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial
    Amminger, G. Paul
    Schafer, Miriam R.
    Papageorgiou, Konstantinos
    Klier, Claudia M.
    Cotton, Sue M.
    Harrigan, Susan M.
    Mackinnon, Andrew
    McGorry, Patrick D.
    Berger, Gregor E.
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2010, 67 (02) : 146 - 154
  • [4] Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects
    Anderson, George
    Maes, Michael
    [J]. METABOLIC BRAIN DISEASE, 2012, 27 (02) : 113 - 119
  • [5] Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia
    Arvindakshan, M
    Ghate, M
    Ranjekar, PK
    Evans, DR
    Mahadik, SP
    [J]. SCHIZOPHRENIA RESEARCH, 2003, 62 (03) : 195 - 204
  • [6] Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group
    Assies, J
    Lieverse, R
    Vreken, P
    Wanders, RJA
    Dingemans, PMJA
    Linszen, DH
    [J]. BIOLOGICAL PSYCHIATRY, 2001, 49 (06) : 510 - 522
  • [7] CHILDHOOD SCHIZOPHRENIA
    Bender, Lauretta
    [J]. PSYCHIATRIC QUARTERLY, 1953, 27 (04) : 663 - 681
  • [8] Bentall R.P., 2009, DOCTORING MIND WHY P
  • [9] N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
    Berk, Michael
    Copolov, David
    Dean, Olivia
    Lu, Kristy
    Jeavons, Sue
    Schapkaitz, Ian
    Anderson-Hunt, Murray
    Judd, Fiona
    Katz, Fiona
    Katz, Paul
    Ording-Jespersen, Sean
    Little, John
    Conus, Philippe
    Cuenod, Michel
    Do, Kim Q.
    Bush, Ashley I.
    [J]. BIOLOGICAL PSYCHIATRY, 2008, 64 (05) : 361 - 368
  • [10] Oxidative stress in schizophrenia: An integrated approach
    Bitanihirwe, Byron K. Y.
    Woo, Tsung-Ung W.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2011, 35 (03) : 878 - 893